Biogen Inc (BIIB) : Fourpoints Investment Managers S.a.s. reduced its stake in Biogen Inc by 3.36% during the most recent quarter end. The investment management company now holds a total of 12,950 shares of Biogen Inc which is valued at $4,065,523 after selling 450 shares in Biogen Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Biogen Inc makes up approximately 2.69% of Fourpoints Investment Managers S.a.s.’s portfolio.
Other Hedge Funds, Including , Gareth Morgan Investments Limited Partnership added BIIB to its portfolio by purchasing 36,792 company shares during the most recent quarter which is valued at $11,550,480. Biogen Inc makes up approx 1.08% of Gareth Morgan Investments Limited Partnership’s portfolio.Capital Advisors Incok boosted its stake in BIIB in the latest quarter, The investment management firm added 1,792 additional shares and now holds a total of 21,776 shares of Biogen Inc which is valued at $6,848,334. Biogen Inc makes up approx 1.02% of Capital Advisors Incok’s portfolio.Pax World Management boosted its stake in BIIB in the latest quarter, The investment management firm added 12,150 additional shares and now holds a total of 19,469 shares of Biogen Inc which is valued at $6,122,806. Biogen Inc makes up approx 0.34% of Pax World Management’s portfolio.Zurcher Kantonalbank (zurich Cantonalbank) reduced its stake in BIIB by selling 3,218 shares or 9.29% in the most recent quarter. The Hedge Fund company now holds 31,417 shares of BIIB which is valued at $10,095,539. Biogen Inc makes up approx 0.13% of Zurcher Kantonalbank (zurich Cantonalbank)’s portfolio.Pitcairn Co boosted its stake in BIIB in the latest quarter, The investment management firm added 1,099 additional shares and now holds a total of 5,995 shares of Biogen Inc which is valued at $1,728,658. Biogen Inc makes up approx 0.22% of Pitcairn Co’s portfolio.
Biogen Inc opened for trading at $316.81 and hit $322.99 on the upside on Tuesday, eventually ending the session at $318.17, with a gain of 0.43% or 1.36 points. The heightened volatility saw the trading volume jump to 14,29,298 shares. Company has a market cap of $69,718 M.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.